Benchtop Automated ELISA Platform Achieves Consistent Biomarker Detection
Posted on 06 Apr 2023
There is growing demand across the scientific and clinical research fields for an immunoassay solution that is both fast and efficient, while ensuring precise and reliable analysis of biomarkers. Furthermore, researchers aim for a higher analysis speed, producing fully analyzed data in less time without sacrificing long-term consistency. Automation offers an opportunity to enhance the efficiency of critical quality steps throughout the discovery to commercialization continuum, while reducing sources of variability and operator bias to provide more accurate and reliable results.
The Ella automated immunoassay instrument from Bio-Techne Corporation (Minneapolis, MN, USA) streamlines the laborious manual process associated with traditional immunoassays, delivering quicker results, increased lab efficiency and reduced human error. The automation of key steps in the assay workflow ensures high levels of reproducibility and data quality, which are crucial factors in research and translational applications.
Manufactured under Bio-Techne's ProteinSimple brand, Ella represents a significant advancement in immunoassays. In less than 90 minutes, it delivers highly reproducible assay data with consistent biomarker detection, and without the need for any manual steps. The assay performance behind that data includes sub-picogram level sensitivity, 4+ logs of dynamic range, and precision which equals the best laboratory automation. With an expanding assay menu of over 250 analytes, Ella supports therapeutic areas across neuroscience, cell and gene therapy, immunology, and cancer. Bio-Techne has achieved a significant milestone, with over 1,000 Ella automated immunoassay instruments now in use.
"We are proud of Ella's contributions towards our mission to catalyze advances in science and medicine." said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We look forward to celebrating new milestones in the future with Ella as the underlying need for greater analytical speed, precision, and reproducibility remains a core driver across clinical and research sectors."
Related Links:
Bio-Techne Corporation
